Trial Profile
A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 24 Jul 2023 Status changed from active, no longer recruiting to completed.
- 30 May 2023 Planned End Date changed from 13 Sep 2023 to 15 Jun 2023.
- 21 Nov 2022 Planned End Date changed from 23 Aug 2023 to 13 Sep 2023.